X, Z., L, S., Y, W., J, L., J, Z., R, C., . . . H, Y. (2021). Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press.
Chicago Style (17th ed.) CitationX, Zhao, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press, 2021.
MLA (8th ed.) CitationX, Zhao, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.